The in vivo effect of thymic factor (thymostimulin) administration on circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease patients.

1983 ◽  
Vol 1 (2) ◽  
pp. 117-125 ◽  
Author(s):  
A Velardi ◽  
F Spinozzi ◽  
P Rambotti ◽  
A Tabilio ◽  
A Losito ◽  
...  
Keyword(s):  
Immune Complexes ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Serum Levels ◽  
Mean Value ◽  
Circulating Immune Complexes ◽  
Calf Thymus ◽  
Serum Lysozyme ◽  
Thymic Factor

The in vivo effect of a calf thymus extract, thymostimulin, on the levels of circulating immune complexes (CIC) and serum lysozyme was evaluated in 32 patients with untreated Hodgkin's disease. Using the platelet aggregation test for detecting CICs, 12 patients (37%) had positive titers before thymostimulin treatment; 3 patients (10%) remained positive following therapy. Serum levels of Clq-binding immune complexes were evaluated (greater than 24.5 micrograms/ml) in 8 patients prior to thymostimulin therapy (mean value: 42.3 micrograms/ml); 3 patients continued to have elevated levels after treatment. Serum lysozyme levels for Hodgkin's patients was similar to control values (10.6 vs. 8.3 micrograms/ml); however, the Hodgkin's patients with initially elevated CICs had a lower serum lysozyme level than patients with initially normal CICs (12.9 vs. 7.3, p less than 0.02). Thymostimulin increased serum lysozyme levels in the Hodgkin's patients in whom the CICs were initially elevated (7.3 vs. 10.4 micrograms/ml, p less than 0.05). These data suggest that thymostimulin exerts an effect on the nonspecific immune system of Hodgkin's disease patients.

scholarly journals The in vivo effect of a thymic factor (thymostimulin) on immunologic parameters of patients with untreated Hodgkin's disease

Cancer ◽  
1982 ◽  
Vol 50 (3) ◽  
pp. 490-497 ◽  
Author(s):  
M. F. Martelli ◽  
A. Velardi ◽  
P. Rambotti ◽  
C. Cernetti ◽  
A. Bertotto ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Thymic Factor ◽  
Immunologic Parameters

Circulating immune complexes in Hodgkin's disease

1978 ◽  
Vol 64 (2) ◽  
pp. 289-294 ◽  
Author(s):  
C.Alan Brown ◽  
Clive L. Hall ◽  
John C. Long ◽  
Kathleen Carey ◽  
Sigmund A. Weitzman ◽  
...  
Keyword(s):  
Immune Complexes ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Circulating Immune Complexes

CIRCULATING IMMUNE COMPLEXES AND SYMPTOMS IN HODGKIN'S DISEASE

The Lancet ◽  
1976 ◽  
Vol 307 (7957) ◽  
pp. 449-451 ◽  
Author(s):  
P.L. Amlot ◽  
B.D. Williams ◽  
J.M. Slaney
Keyword(s):  
Immune Complexes ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Circulating Immune Complexes

scholarly journals Evaluation of Serum Immunoglobulins (IgG, IgA, IgM) and Circulating Immune Complexes in Oral Precancer and Cancer Patients

2021 ◽  
Author(s):  
Pooja Madki ◽  
Mandya Lakshman Avinash Tejasvi ◽  
Geetha Paramkusam ◽  
Ruheena Khan ◽  
Shilpa J.
Keyword(s):  
Oral Cancer ◽  
Immune Complexes ◽  
Serum Levels ◽  
Circulating Immune Complexes ◽  
Oral Cancers ◽  
Cancer Group ◽  
Oral Precancer ◽  
Serum Iga ◽  
The Mean

Abstract Objectives The aim of the present study is to evaluate the role of immunoglobulins (IgA, IgG, and IgM) and circulating immune complexes (CIC) as tumor marker in oral cancer and precancer patients. Materials and Methods The present study was performed on 45 individuals subdivided into three groups, that is, oral precancer, oral cancer and healthy individuals, and levels of immunoglobulins, and CIC was estimated by turbidometry and ELISA method. Results In the present study, the mean serum IgA levels in oral precancer were 161.00 ( ±  118.02) mg/dL, oral cancers were 270.67 ( ±  171.44) mg/dL, and controls were 133.73 ( ±  101.31) mg/dL. Mean serum levels of IgG in oral precancer were 1,430.87 ( ±  316) mg/dL, oral cancers were 1,234.27 ( ±  365.42) mg/dL, and controls were 593.87 ( ±  323.06) mg/dL. Conclusion We found that the levels of serum IgG and IgA were elevated consistently in precancer and cancer group, and Serum IgM levels were increased only in precancer. Also, significant increase in serum CIC levels were seen in oral precancer and cancer group on comparison with control.

Detection of Circulating Immune Complexes in the Sera of Rabbits with Experimental Syphilis: Possible Role in Immunoregulation

1980 ◽  
Vol 29 (2) ◽  
pp. 575-582
Author(s):  
Robert E. Baughn ◽  
Kenneth S. K. Tung ◽  
Daniel M. Musher
Keyword(s):  
Immune Complexes ◽  
Proteolytic Enzymes ◽  
Suppressor Cell ◽  
Suppressive Effect ◽  
Circulating Immune Complexes ◽  
Time Period ◽  
Infected Cells ◽  
Disseminated Disease

The in vivo and in vitro immunoglobulin G plaque-forming cell responses to sheep erythrocytes (SRBC) are nearly obliterated during disseminated syphilitic infection (3 to 8 weeks post-intravenous injection) in rabbits. Splenic and lymph node cells obtained from infected rabbits during this time period were capable of suppressing the normal in vitro responses of uninfected, SRBC-primed cells. Cell-free washings of cells from infected animals were also suppressive. This finding coupled with the fact that treatment of infected cells with proteolytic enzymes abrogated the suppressive effect constitute arguments against involvement of a specific suppressor cell population. The incidence of elevated levels of circulating immune complexes in the sera of rabbits with disseminated disease was also significantly different from that of uninfected controls or infected rabbits before the onset or after the regression of lesions. When added to cultures of lymphocytes from uninfected, SRBC-sensitized rabbits, sera containing complexes caused dose-related suppression of the in vitro immunoglobulin responses. Unlike immune complexes, no correlation was found between the presence of mucopolysaccharide materials and the stage of infection or the ability of serum to suppress the immunoglobulin responses to SRBC.

scholarly journals Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Treatment of Patients With EBV-Positive Relapsed Hodgkin's Disease

Blood ◽  
1998 ◽  
Vol 91 (8) ◽  
pp. 2925-2934 ◽  
Author(s):  
Marie A. Roskrow ◽  
Nobuhiro Suzuki ◽  
Yan-jun Gan ◽  
John W. Sixbey ◽  
Catherine Y.C. Ng ◽  
...  
Keyword(s):  
Tumor Cells ◽  
Cytotoxic T Lymphocytes ◽  
Hodgkin's Disease ◽  
Epstein Barr Virus ◽  
Hodgkin’S Disease ◽  
Barr Virus ◽  
Specific Ctls ◽  
Epstein Barr ◽  
Relapsed Disease

Adoptive transfer of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) is effective prophylaxis and treatment of EBV-positive immunoblastic lymphoma in immunocompromised patients. In 50% of patients with Hodgkin's disease, the tumor cells are EBV antigen-positive and may therefore also be suitable targets for treatment with virus-specific CTLs. However, Hodgkin's disease may produce several inhibitory effects on immune induction and effector function in vivo, which may preclude the generation or effector function of CTLs reactive against EBV viral proteins, including those expressed by the tumor cells. We have investigated whether EBV-specific CTLs could be generated ex vivo from 13 patients with Hodgkin's disease: nine with active relapsed disease and four who were in clinical remission after a first or subsequent relapse. CTL lines were successfully generated from nine of 13 patients (five active disease, four remission). Although these lines had an abnormal pattern of expansion comparable to EBV-specific CTLs generated from normal donors, their phenotype was normal except for reduced expression of the zeta chain of the T-cell receptor (TCR). Their cytotoxicity was also compared to EBV-specific lines generated from normal donors and included activity against LMP2a, one of the three weakly immunogenic viral antigens expressed by Hodgkin's tumor cells. To assess the activity of the CTLs in vivo, they were gene-marked and infused into three patients with multiply relapsed disease. The CTLs persisted for more than 13 weeks postinfusion and retained their potent antiviral effects in vivo, thereby enhancing the patient immune response to EBV. This approach may therefore have value in the treatment of EBV-positive Hodgkin's disease.

scholarly journals Numerical chromosome aberrations are present within the CD30+ Hodgkin and Reed-Sternberg cells in 100% of analyzed cases of Hodgkin's disease [see comments]

Blood ◽  
1995 ◽  
Vol 86 (4) ◽  
pp. 1464-1468 ◽  
Author(s):  
K Weber-Matthiesen ◽  
J Deerberg ◽  
M Poetsch ◽  
W Grote ◽  
B Schlegelberger
Keyword(s):  
Chromosome Numbers ◽  
Chromosome Aberrations ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Considerable Variability ◽  
Karyotype Instability ◽  
Numerical Aberrations ◽  
Numerical Chromosome

In Hodgkin's disease, cytogenetically aberrant clones have been demonstrated in a minority of cases studied. In the remaining cases, only normal metaphases have been found, but it is questionable whether normal karyotypes actually correspond to the pathognomonic Hodgkin and Reed-Sternberg (HRS) cells. Numerical aberrations could be studied by fluorescence in situ hybridization (FISH). However, in Hodgkin's disease, the percentage of tumor cells is mostly below the detection limit of FISH, which is near 1%. With the technique of simultaneous fluorescence immunophenotyping and interphase cytogenetic analysis (FICTION), this problem can be overcome. By FICTION, hybridization signals can selectively be evaluated within the CD30a+ cell population. We have studied 30 cytogenetically analyzed cases of Hodgkin's disease by means of FICTION. In all cases, we found numerical chromosome aberrations within the majority of CD30+ HRS cells. In cases with complex and hyperdiploid karyotypes, the cytogenetic results agreed with the FICTION data. There was considerable variability in the chromosome numbers, demonstrating that karyotype instability is an in vivo phenomenon of HRS cells. Lymphocytes never displayed numerical chromosome changes. Our results indicate that HRS cells regularly exhibit numerical chromosome aberrations and that the chromosome numbers are always in the hyperploid range.

Sign in / Sign up

Export Citation Format

Share Document